Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is well-positioned to make a significant impact in the therapeutics industry with its innovative Glyph platform and promising drug candidates for neuropsychiatric disorders. The company has a strong pipeline and experienced leadership, and their recent investment in property highlights their commitment to growth and success. With positive results in clinical trials and the potential for further acquisitions, Seaport Therapeutics has a positive outlook for investors.

Bears say

Seaport Therapeutics is a clinical-stage pharmaceutical company that utilizes its Glyph platform to enhance the oral bioavailability and reduce side effects of drugs through lymphatic-targeting prodrugs. Their lead products, GlyphAllo and GlyphAgo, have shown promising results in Phase 1 and Phase 2a trials for the treatment of depression and anxiety, respectively. However, the company's overall outlook is negative due to the inherent risks associated with the neuropsychiatry market, competition from other neuroplastogens, and the inconsistent dosing response and potential safety concerns of AGO in the US. Additionally, while the Glyph platform may mitigate some risks, there is still uncertainty surrounding the scheduling and potential long-term safety of their lead products. With a relatively small pipeline and limited clinical evidence, the company's stock may not see significant upside even if one of their lead products is successful.

SPTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, SPTX has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.